ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
06 May 2024 07:30

HK Strategy: Where Are the Short-Term Opportunities?

Li Auto, Link REIT, China Mengniu, Hang Lung Properties, and Galaxy Entertainment are massive laggards YTD but the recent rebound from the trough...

Logo
420 Views
Share
26 Apr 2024 11:39

Hong Kong Buybacks Weekly (Apr 26th): Hang Seng Bank, Xiaomi, Wuxi Biologics

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Hang Seng Bank (11...

Logo
287 Views
Share
bearishWuXi XDC Cayman
01 Apr 2024 08:55

WuXi XDC Cayman (2268.HK) - Don't Rush to Bottom Fish This Stock

Due to geopolitical conflicts, there is “a hesitation” towards sustained high growth of WuXi XDC. This helps explain why WuXi XDC posted high...

Logo
341 Views
Share
24 Mar 2024 10:00

HK Short Interest Weekly: Techtronic Ind, Zijin Mining, Innovent Bio, Kuaishou, Pacific Basin

We analyzed the latest HK SFC report for aggregate short position as of Mar 15th and highlight short interest changes in Techtronic Ind, Zijin...

Logo
347 Views
Share
bullishGanfeng Lithium
17 Mar 2024 00:54

A/H Premium Tracker (To 15 Mar 2024):  Liquid AH Premia Starting to Narrow

AH Premia narrowed more on liquid narrow premia than on less liquid and wide premia. This is a new development. Energy and Utilities saw Hs rebound...

Logo
468 Views
Share
x